Figure 1:

Estimated number of cancer cases averted by mid-adult vaccination through age 45 years: The cumulative number of cancer cases averted by vaccination of females and males aged 12–45 years vs. the comparison strategy (vaccination of females aged 12–26 years, and males aged 12–21 years), by cancer site (oropharyngeal, cervical, anal, vaginal and vulvar, and penile) over the 100-year vaccination program. The mid-adult vaccination strategy was assumed to be implemented in year 12 of the vaccine program (i.e., in the mid-adult vaccination strategy, the cutoff age of catch-up vaccination was set at 26 years for women and 21 years for men in years 1 through 11 of the vaccination program and was later increased to age 45 years in years 12 through 100). These outcomes were not discounted.